Selpercatinib is indicated for the treatment of adult patients with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with lenvatinib and/or sorafenib.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||08/06/2021|
|Rapid review completed||07/07/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care.|